Treatment of nonpsychotic relatives of patients with schizophrenia: Six case studies

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 114, Issue 8, 2002, Pages 943-948

  Tsuang, Ming T ^a,b,c,d,e   Stone, William S ^a,b,c   Tarbox, Sarah I ^a   Faraone, Stephen V ^a,b,c,e  

^a MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; CLINICAL ARTICLE; COGNITION; DRUG EFFICACY; FAMILY; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; CASE REPORT; NEUROLOGIC DISEASE; PSYCHOLOGICAL ASPECT;

FAMILY; HUMANS; NERVOUS SYSTEM DISEASES; SCHIZOPHRENIA;

EID: 1842842727     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.10363     Document Type: Article

References (38)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Press.
2. Andreasen NC. 1983. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa.
3. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJP, Frank JA, Weinberger DR. 1998. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype. Biol Psychiatry 44:941-950.
4. Catts SV, McConaghy N, Ward PB, Fox AM, Hadzi-Pavlovic D. 1993. Allusive thinking in parents of schizophrenics. Meta-analysis. J Nerv Ment Dis 181:298-302.
5. Chapman LJ, Chapman JP. 1978. The measurement of differential deficit. J Psychiatric Res 14:303-311.
6. Cornblatt BA, Keilp JG. 1994. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 20:31-46.
7. Cornblatt B, Winters L, Erlenmeyer-Kimling L. 1989. Attentional markers of schizophrenia: Evidence from the New York high-risk study. In: Schulz SC, Tamminga CA, editors. Schizophrenia: Scientific Progress. New York: Oxford University Press. p 83-92.
8. Derogatis LR. 1993. Symptom Checklist-90-R (SCL-90-R). Minneapolis, MN: Computer Systems, Inc.
9. Erlenmeyer-Kimling L, Cornblatt B, Friedman D, Marcuse Y, Rutschmann J, Simmens S, Devi F. 1982. Neurological, electrophysiological, and attentional deviations in children at risk for schizophrenia. In: Henn FA, Nasrallah HA, editors. Schizophrenia as a Brain Disease. New York: Oxford University Press. p 61-98.
10. Erlenmeyer-Kimling L, Cornblatt B, Rock D, Roberts S, Bell M, West A. 1993. The New York high-risk project: Anhedonia, attentional deviance, and psychopathology. Schizophr Bull 19:141-153.
11. Faraone SV, Kremen WS, Lyons MJ, Pepple JR, Seidman LJ, Tsuang MT. 1995. Diagnostic accuracy and linkage analysis: How useful are schizophrenia spectrum phenotypes? Am J Psychiatry 152:1286-1290.
12. Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Lyons MJ, Tsuang MT. 1995. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: A diagnostic efficiency analysis. J Abnorm Psychol 104:286-304.
13. Faraone SV, Seidman LJ, Kremen WS, Toomey R, Pepple JR, Tsuang MT. 1999. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: A four-year follow-up study. J Abnorm Psychology 108:176-181.
14. Faraone SV, Seidman LJ, Kremen WS, Toomey R, Pepple JR, Tsuang MT. 2000. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: The effect of genetic loading. Biol Psychiatry 48:120-126.
15. Faraone SV, Green AI, Seidman LJ, Tsuang MT. 2001. "Schizotaxia": Clinical implications and new directions for research. Schizophr Bull 27: 1-18.
16. Friedman D, Squires-Wheeler E. 1994. Event-related potentials (ERPs) as indicators of risk for schizophrenia. Schizophr Bull 20:63-74.
17. Green AI, Schildkraut JJ. 1995. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard Rev Psychiatry 3:1-9.
18. Green MF, Marshall BDJ, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. 1997. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154: 799-804.
19. Heinrichs DW, Hanlon ET, Carpenter WT. 1984. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388-398.
20. Kendler KS, Lieberman JA, Walsh D. 1989. The structured interview for schizotypy (SIS): A preliminary report. Schizophr Bull 15:559-571.
21. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV. 1994. Neuropsychological risk indicators for schizophrenia: A review of family studies. Schizophr Bull 20:103-119.
22. Levy DL, Holzman PS, Matthysse S, Mendell NR. 1994. Eye tracking and schizophrenia: A selective review. Schizophr Bull 20:47-62.
23. Marder S, Meibach R. 1994. Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
24. Meehl PE. 1962. Schizotaxia, schizotypy, schizophrenia. Am Psychol 17: 827-838.
25. Meehl PE. 1989. Schizotaxia revisited. Arch Gen Psychiatry 46:935-944.
26. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T, Miller M, Bowman ES, DePaulo JR, Cloninger CR, Robinson G, Moldin S, Gershon ES, Maxwell E, Guroff JJ, Kirch D, Wynne D, Berg K, Tsuang MT, Faraone SV, Pepple JR, Ritz AL. 1994.
27. Seidman LJ. 1997. Clinical neuroscience and epidemiology in schizophrenia. Harvard Rev Psychiatry 3:338-342.
28. Seidman LJ, Cassens G, Kremen WS, Pepple JR. 1992. The Neuropsychology of Schizophrenia. Amsterdam: Elsevier Biomedical Publishers.
29. Seidman LJ, Faraone SV, Goldstein JM, Goodman JM, Kremen WS, Matsuda G, Hoge EA, Kennedy DN, Makris N, Caviness VS, Tsuang MT. 1997. Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients: A pilot MRI study. Am J Med Genet 74:507-514.
30. Seidman LJ, Faraone SV, Goldstein JM, Goodman JM, Kremen WS, Toomey R, Tourville J, Kennedy D, Makris N, Caviness VS, Tsuang MT. 1999. Thalamic and amygdala-hippocampal volume reductions in first degree relatives of schizophrenic patients: An MRI-based morphometric analysis. Biol Psychiatry 46:941-954.
31. Stip E. 1996. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 41:S35-S40.
32. Tamminga CA. 1997. The promise of new drugs for schizophrenia treatment. Can J Psychiatry 42:265-273.
33. Toomey R, Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Tsuang MT. 1998. Association of vulnerability markers in relatives of schizophrenic patients. Schizophr Res 31:89-98.
34. Tsuang MT, Gilbertson MW, Faraone SV. 1991. Genetic transmission of negative and positive symptoms in the biological relatives of schizophrenics. In: Marneros A, Tsuang MT, Andreasen N, editors. Positive vs. Negative Schizophrenia. New York: Springer-Verlag. p 265-291.
35. Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, Kelleher J, Green AI. 1999. Treatment of nonpsychotic relatives of patients with schizophrenia: Four case studies. Biol Psychiatry 41: 1412-1418.
36. Voglmaier MM, Seidman LJ, Salisbury D, McCarley RW. 1997. Neuropsychological dysfunction in schizotypal personality disorder: A profile analysis. Biol Psychiatry 41:530-540.
37. Weissman MM, Bothwell S. 1976. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 33:1111-1115.
38. Wyatt RJ. 1995. Early intervention for schizophrenia: Can the course of the illness be altered? Biol Psychiatry 38:1-3.